Bengaluru, along with Hyderabad, NCR Delhi, and Chennai, is a major hub for these centers, making up 74% of the new ones.

(Image Credits: Pixabay) Gennova Biopharmaceuticals Ltd. on Tuesday announced that it is partnering with the Coalition for Epidemic Preparedness Innovations (CEPI), a subsidiary of Emcure ...

Currently there are no authorized vaccines or targeted drugs against Nipah, which kills an estimated 75% of those it infects.

Gennova Biopharmaceuticals in Pune has developed HGCO19, an innovative mRNA vaccine candidate that doesn’t require ultra-cold storage — a critical advantage for tropical countries like India.

New Delhi: Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, on Tuesday announced a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) for advancing the ...

Pune-based Gennova Biopharmaceuticals Ltd will develop a self-amplifying mRNA vaccine candidate against the deadly Nipah virus. The critical initiative is supported by an expanded partnership with the ...

Pune: Emcure Pharmaceuticals Ltd. subsidiary Gennova Biopharma ceuticals Ltd., is advancing the development of a pathbreaking self-amplifying mRNA (saRNA) vaccine against the deadly Nipah virus. This ...

Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, has announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a ...

Please find enclosed herewith a Press Release titled Gennova Advances Pathbreaking AI-Enhanced saRNA Vaccine for one of the deadliest known viruses in collaboration with CEPI by Gennova ...